Quince Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-31. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
Conditional Resignations of Dirk Thye and Brendan Hannah On July 29, 2026, each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the " Company "), and a member of the Company's board of directors (the " Board "), and Brendan Hannah, the Company's Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company (including, with respect to Mr. Thye, as a member of the Board), in each case effective as of two business days following the conclusion of the Company's
Appointed: Brigette Roberts, Director
Appointment of Directors In accordance with the Merger Agreement, on May 18, 2026, effective immediately after the Effective Time, Brigette Roberts, M.D., was appointed to the Board as a Class III director.
Reported
On April 22, 2026, the Board of Directors (the "Board") of Quince Therapeutics, Inc. (the "Company") increased the number of directors on the Board to four and appointed June Bray as a Class I director of the Company to fill the resulting vacancy, effective immediately, to serve until the 2026 Annual Meeting of Stockholders, or until her earlier death, disqualification, resignation or removal.
Quince Therapeutics, Inc.'s funding history
Find people with the same kind of experience as the Director at Quince Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Quince Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Quince Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Quince Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Quince Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.